“Novavax should be approved within a month.”
Reuters reported on 12 March:
“Novavax Inc’s COVID-19 vaccine was 96 per cent effective in preventing cases caused by the original version of the coronavirus in a late-stage trial conducted in the United Kingdom... 86 per cent effective in protecting against the more contagious virus variant first discovered and now prevalent in the United Kingdom (Kent variant).”